FDA Informed Consent Guidance Under Development; HIV Studies Present Unique Challenges
Executive Summary
When early “cure” research is unlikely to lead to study participants’ own HIV cure, the informed consent hurdle is high, patients told FDA. But will new guidance offer sufficient help and a successful path forward?
You may also be interested in...
Patient Input Comes Full Circle: Ex-FDAer Gives Feedback To FDA
US agency's April 6 patient-focused drug development meeting on sarcopenia sent two very divergent messages about the status of measuring patient engagement on new drug development: both delivered by an unexpected messenger, former FDAer Ray Lipicky.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests
The rulemaking is supposed to formalize the Patent Trial and Appeal Board process, which has been in an interim status since a Supreme Court decision, giving manufacturers more ability to request oversight of the decisions.